vimarsana.com

Latest Breaking News On - Stern investor - Page 9 : vimarsana.com

Bio Path Holdings Inc (BPTH) CEO Peter Nielsen on Q1 2022 Results - Earnings Call Transcript

Akouos Reports First Quarter 2022 Financial Results and Provides Business Highlights

Akouos Reports First Quarter 2022 Financial Results and Provides Business Highlights
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Akouos Appoints Stacy Price as Chief Technical Officer

BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene.

Akouos Appoints Stacy Price as Chief Technical Officer

Akouos Appoints Stacy Price as Chief Technical Officer - read this article along with other careers information, tips and advice on BioSpace

Oncoinvent Secures NOK 250 M in an oversubscribed Pre-IPO Funding Round

Press release content from Business Wire. The AP news staff was not involved in its creation. Oncoinvent Secures NOK 250 M in an oversubscribed Pre-IPO Funding Round June 29, 2021 GMT OSLO, Norway (BUSINESS WIRE) Jun 29, 2021 Norway Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, announced today that the company has raised NOK 250 million in an oversubscribed pre-IPO financing round syndicated by existing investors Hadean Ventures, Geveran, RADFORSK Investeringsstiftelse, Sundt, Must Invest, Canica, MP Pensjon and Watrium. The net proceeds from the Private Placement are expected to ensure financing past end of 2023 for its lead product candidate Radspherin®, including financing of two clinical phase 2A studies (in ovarian cancer and colorectal cancer) as well as the advancement of the company’s proprietary targeted radiotherapy candidates. Oncoinvent has raised a total of NOK 535 million to date.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.